Surgery Partners (NASDAQ:SGRY) Director Purchases $143,500.00 in Stock

Surgery Partners, Inc. (NASDAQ:SGRY) Director Teresa Deluca purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average price of $14.35 per share, for a total transaction of $143,500.00. Following the purchase, the director owned 66,843 shares in the company, valued at $959,197.05. This represents a 17.59% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Surgery Partners Stock Performance

Shares of SGRY stock opened at $14.52 on Friday. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -20.74, a price-to-earnings-growth ratio of 3.78 and a beta of 1.91. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.78 and a current ratio of 1.95. Surgery Partners, Inc. has a one year low of $11.41 and a one year high of $23.79. The company’s 50-day moving average is $15.57 and its 200 day moving average is $14.39.

Surgery Partners (NASDAQ:SGRY) last issued its earnings results on Monday, August 10th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.04. The business had revenue of $848.90 million during the quarter, compared to analysts’ expectations of $830.03 million. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.88%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.17 earnings per share. Sell-side analysts expect that Surgery Partners, Inc. will post 0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SGRY shares. Royal Bank Of Canada lowered their price objective on Surgery Partners from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of Surgery Partners in a report on Tuesday, August 11th. Raymond James Financial set a $18.00 target price on Surgery Partners in a report on Tuesday, August 11th. Zacks Research cut Surgery Partners from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Finally, TD Cowen upped their price target on Surgery Partners from $17.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.45.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Jupiter Topco LLC purchased a new stake in Surgery Partners in the second quarter worth approximately $233,220,000. Pentwater Capital Management LP bought a new stake in Surgery Partners in the 2nd quarter worth approximately $195,384,000. BlackRock Inc. purchased a new stake in Surgery Partners during the 2nd quarter valued at $104,857,000. UBS Group AG raised its stake in Surgery Partners by 111.4% during the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock valued at $120,571,000 after buying an additional 4,113,052 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Surgery Partners during the 2nd quarter valued at $48,912,000.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.